The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
Sasika NV Dewage, Louise Organ, Emmanuel Koumoundouros, Habtamu B Derseh, Kopiyawaththage UE Perera, Chrishan S Samuel, Andrew W Stent, Ken J Snibson
Experimental Lung Research | Taylor & Francis | Published : 2020
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with unknown cause. While the drugs nintedanib and pirfenidone have been approved for the treatment of IPF, they only slow disease progression and can induce several side-effects, suggesting that there is still an unmet need to develop new efficacious drugs, and interventions strategies, to combat this disease. We have recently developed a sheep model of pulmonary fibrosis for the preclinical testing of novel anti-fibrotic drugs. The aim of this study was to assess the effects of pirfenidone to ascertain its suitability as a benchmark for comparing other novel therapeutics in this sheep model. To initiate loca..View full abstract